

TABLE 1

Expression of Huntington's Disease Mutation in Mice

Model design				Behavioral disorder			Neuropathology		
LAB	Background	Promoter/ gene size/ CAG repeats	Protein expression level	Clasping Phenotype	Rotarod	Other symptoms	NII Cell Pathology	Cell Loss	Brain Atrophy
Transgenic HD models									
Bates ¹	CBA/ C57Bl6	HD promoter exon 1 R6/2 144Q (expanded to 170 - 190 Q), R6/1 115 Q	RNA levels < 1x	Onset 2 mo. (R6/1 onset 5 mo.)	Abnormal by 5 weeks	Tremors & abnormal gait, learning deficit, hypokinesis, diabetes	NII and neuropil aggregates throughout brain, fewer dendritic spines, depol. Str. Cells	Frontal cortex, dorsal striatum and cerebellar Purkinje cells at late stage	Overall brain atrophy
Hayden ²	FVB/N	HD YAC Full-length 72Q, 46Q, 18Q	2X	72Q (#2498) onset by 3 mo.	not reported	Hyperactive & circling	Inclusions in striatum	Cell loss in striatum	not reported
Ross/Borchelt ³	C3H/Bl6	PrP prom. N171 82Q, 44Q, 18Q	1/5X to 1/10X	82Q onset 5 mo.	Abnormal by 3 mo.	Tremors & abnormal gait, hypokinesis, weight loss, early death	Inclusions: striatum, ctx, hippocampus, amygdala, cb. Diffuse nuclear accumu. of htt protein	toluidine blue reveals cells w/a degenerative morphology in the lateral striatum	Overall brain atrophy
Tagle ^{4, 5, 6}	FVB/N	CMV prom. Full-length 89Q, 48Q, 16Q	5X	89Q&48Q onset 4 mo.	not reported	Circling, hyperactivity, end-stage hypoactivity & urinary incontinence	Fewer inclusions throughout brain	20% cell loss in striatum of some animals	not reported
	FVB/N	CMV prom Ex1-3, 89Q	Endogenous to 2x	ex1-3:89Q onset 4 mon.	not measured	Prolonged Hyperactivity	Fewer inclusions throughout the brain	not reported	not reported
Aronin/ DiFiglia ⁷	SJL/ C57Bl6	rat NSE 3 kb fragment 100Q, 48Q, 18Q	>endogenous about 1/5X	100Q onset 3-4 mo.	Abnormal about 4 mo.	Hyperactivity to endstage hypoactivity	Inclusions in Q100 (few in Q46), DNs observed	20% cell loss ~ 8mo. in some animals	Brain atrophy in some animals
Hen/Yamamoto ⁸	CBA/ C57Bl6	tet-off (CamKIIα-tTA) TetO Exon1 94Q	>endogenous	94Q onset in 50% by 2.5 mo.	Onset about 2.5 mo.	Late onset tremor & abnormal gait	Inclusions in striatum, septum, ctx, hippo., & reactive astrocytes	not reported	Brain atrophy & progressive striatal atrophy
Targeted Hdh models									
MacDonald/ Joyner ^{9, 10, 11}	129/CD1	Hdh promoter Knock-in 111Q, 92Q, 50Q	endogenous	no movement Sx.	no difficulties found	cellular phenotype see neuropath	CAG- & age- depend. HTT nuclear relocalization at 1.5 mo, inclusion >6 mo.	none observed	not reported
	SW	neo & Hdh prom., Knock-in 111Q,20Q	<50% of endog.	Hdh ^{nQ20/nQ111} have onset ~ 2 mo.	not measured	nQ20/nQ111 show disorders similar to Exon1-Q144 mouse	age- dependent HTT nuclear re-localization and inclusions	none observed	preliminary result: brain atrophy
Myers ¹²	FVB- N/Bl6	Hdh prom., Knock-in 80Q,72Q	2X	no movement Sx.	none reported	Early onset aggressive behavior	Late inclusions, hipp. LTP impaired, repeat instability in striatum	none observed	not reported
Zeitlin ¹³	C57Bl6	Hdh prom., Knock-in 94Q, 71Q	~2X	no movement Sx.	none reported	No movement Sx.; NMDA sensitivity	No inclusions	Striatal cell swelling in response to NMDA	smaller striatal cells
Targeted Non-Hdh polyQ									
Detloff ¹⁴	129/ C57Bl6	x-link Hprt locus 146Q insert	endogenous	Onset ~5 mo.	none reported	Handling-induced seizures & early death	Inclusions throughout brain	None	not reported

Transgenic DRPLA model

Ross/Borchelt 15	C3H/B16	PrP Promotor, full length atrophin-1 cDNA(1184aaa), 65Q and 26Q	about 1-3x (two lines)	less than HD	abnormal by two months	tremors, ataxia, twitchy movements, loss of coordination, seizures, early death	Widespread Inclusions, also accumulation of truncated N-terminal fragment of atrophin, similar to a fragment seen in DRPLA brains	approx. 30% loss in cerebellar Dentate nucleus(site of DRPLA path)	Overall brain atrophy
------------------	---------	---	------------------------	--------------	------------------------	---	---	--	-----------------------

Table Created by Marina Chicurel, Ph.D., Marc S. Hurlbert, Ph.D., Erik Schweitzer, and Ai Yamamoto March 2000

BIBLIOGRAPHY

- Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, and Bates GP. "Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice." *Cell* 87(3):493-506, 1996 Nov 1. *See below for additional papers published on R6 Lines*
- Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Rodger JC, Phillips AG, Rubin EM, Hersch SM, and Hayden MR. "A YAC mouse model for Huntington's disease with Full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration." *Neuron* 23:181-192, May 1992
- Schilling et al. "Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin." *Human Molecular Genetics* 8: 397-407, 1999
- Reddy PH, Williams M, Charles V, Garrett L, Pike-Buchanan L, Whetsell WO Jr, Miller G, and Tagle DA. "Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA." *Nature Genetics* 20(2):198-202, 1998 Oct.
- Reddy, P.H., Charles, V., Williams, M., Miller, G., Whetsell, W.O., Jr., and Tagle, D.A. Transgenic mice expressing mutated full-length cDNA: A paradigm for locomotor changes and selective neuronal loss in Huntington's Disease. *Phil. Trans. Royal Society Biol.* 354, 1037-1046, 1999
- Data on Tagle's truncated models remains unpublished
- DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, and Aronin N. "Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain." *Science* 277(5334):1990-3, 1997 Sep 26.
- Yamamoto A, Lucas JJ and Hen R. "A reversible mouse model of Huntington's Disease." *Society for Neuroscience Abstracts* 1999 (in press).
- White JK, Auerbach W, Duyao MP, Vonsattel JP, Gusella JF, Joyner AL, MacDonald ME. "Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion." *Nature Genetics* 17:404-10, Dec. 1997
- Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Rodger JC, Phillips AG, Rubin EM, Hersch SM, and Hayden MR. "A YAC mouse model for Huntington's disease with Full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration." *Neuron* 23:181-192, May 1992
- Wheeler VC, White JK, Gutekunst CA, Vrbanac V, Weaver M, Li XJ, Li SH, Yi H, Vonsattel JP, Gusella JF, Hersch S, Auerbach W, Joyner AL, MacDonald ME. "Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in Hdh(Q92) and Hdh(Q111) knock-in mice." *Human Molecular Genetics* 9(4):503-513, March 2000.
- Shelbourne PF, Killeen N, Hevner RF, Johnston HM, Tecott L, Lewandowski M, Ennis M, Ramirez L, Li Z, Iannicola C, Littman DR, and Myers RM. "A huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioral abnormalities in mice." *Human Molecular Genetics* 8:763-774, 1999
- Levin MS, Klapstein GJ, Koppel A, Gruen E, Cepeda C, Vargas ME, Jokel ES, Carpenter EM, Zanjani H, Hurst RS, Efstratiadis E, Zeitlin S, Chesselet M-F (1999) Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. *J. Neurosci Res.* 58: 515-532.
- Ordway JM, Tallaksen-Greene S, Gutekunst CA, Bernstein EM, Cearley JA, Wiener HW, Dure LS 4th, Lindsey R, Hersch SM, Jope RS, Albin RL, and Detloff PJ. "Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse." *Cell* 91(6):753-63, 1997 Dec 12.
- Schilling et al. "Nuclear accumulation of truncated atrophin-1 fragments in a transgenic mouse model of DRPLA." *Neuron* 24:275-286, 1999

Additional Papers Published on R6 Lines

- Van Dellon A, Blakemore C, Deacon R, York D, Hannan AJ (2000) Environmental enrichment delays disease onset in a mouse model of Huntington's disease. *Nature* in press.
- Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, Frey AS, Spektor BS, Penney EB, Schilling G, Ross CA, Borchelt DR, Tapscott SJ, Young AB, Cha J-H, Olson JM (2000) Decreased expression of striatal signalling genes in a mouse model of Huntington's disease. *Hum. Mol. Genet.* in press.
- Kerry PSJ, Carter RJ, Lione LA, Mangiarini L, Mahal A, Dunnett SB, Bates GP, Morton AJ. (2000) Novel Synaptic Long-term depression and impaired spatial cognition in mice transgenic for the Human Huntington's Disease mutation. *J. Neurosci.* In press.
- Tabrizi SJ, Workman J, Hart P, Mangiarini L, Mahal A, Bates G, Cooper JM, Schapira AHV (2000) Mitochondrial dysfunction and free radical damage in the R6/2 transgenic mouse model of Huntington's disease. *Annals Neurol.* 47, 80-86
- Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal, A, Bates GP, Morten AJ, Dunnett SB (1999) Characterisation of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. *J. Neurosci.* 19 (8), 3248-3257.
- Cha J-H, Frey AS, Alsdorf SA, Kerner JA, Kosinski CM, Mangiarini L, Penney JB, Davies SW, Bates GP, Young AB (1999) Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. *Phil. Trans. Royal Soc.* 354, 981-989.
- Davies SW, Turmaine M, Cozens BA, Mangiarini L, Bates GP (1999) From neuronal inclusions to neurodegeneration: neuropathological investigations of a transgenic mouse model of Huntington's disease. *Phil. Trans. Royal Soc.* 354, 971-979.
- Hansson O, Peterson A, Leist M, Nicotera P, Castilho RF, Brundin P (1999) Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. *PNAS* 96: 8727-8732.
- Hurlbert MS, Zhou W, Wasmeier C, Kaddis FG, Hutton JC, Freed CR (1999) Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. *Diabetes* 48:649-651.
- Kosinski CM, Cha J-H, Young A, Mangiarini L, Bates GP, Schwarz M (1999) Intranuclear inclusions in subtypes of striatal neurons in Huntington's disease transgenic mice. *Neuroreport* 10, 3891-3896.

11. Li H, Li S-H, Cheng AL, Mangiarini L, Bates GP, Li X-J (1999) Ultrastructural localisation and progressive formation of neuropil aggregates in Huntington disease transgenic mice. *Hum. Mol. Genet.* 8, 1227-1236.
12. Lione LA, Rebecca JC, Hunt MJ, Bates GP, Morton AJ, Dunnet SB (1999) Selective discrimination learning impairments in mice expressing the Huntington's Disease Mutation. *J. Neurosci.* 19(23): 10428-10437.
13. Levin MS, Klapstein GJ, Koppel A, Gruen E, Cepeda C, Vargas ME, Jokel ES, Carpenter EM, Zanjani H, Hurst RS, Efstratiadis E, Zeitlin S, Chesselet M-F (1999) Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. *J. Neurosci Res.* 58: 515-532.
14. Ona VO, Li M, Vonsattel JPG, Andrews LJ, Khan SQ, Chung WM, Frey AS, Menon AS, Li X-J, Stieg PE, Yuan J, Penney JB, Young AB, Cha J-HJ, Friedlander RM (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. *Nature* 399: 263-267.
15. Reynolds GP, Dalton CF, Tillery CL, Mangiarini L, Davies SW, Bates GP (1999) Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation. *J. Neurochem.* 72, 1773-1776.
16. Sathasivam K, Hobbs C, Turmaine M, Mangiarini L, Mahal A, Bertaux F, Wanker EE, Doherty P, Davies SW, Bates GP (1999) Formation of polyglutamine inclusions in non-CNS tissue. *Hum. Mol. Genet.* 8, 813-822.
17. Sathasivam K, Hobbs C, Mangiarini L, Mahal A, Turmaine M, Doherty P, Davies SW, Bates GP. (1999) Transgenic models of Huntington's disease. *Phil. Trans. Royal Soc.* 354, 963-969.
18. Cha J-H, Kosinski C, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, Penney JB, Bates GP, Young A (1998) Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal Huntington's disease gene. *PNAS* 95, 6480-6485.
19. Dunnett, SB, Carter, RJ, Watts, C, Torres, EM, Mahal, A, Mangiarini, L, Bates, G, Morton, AJ (1998) Striatal transplantation in a transgenic mouse model of Huntington's disease. *Exp. Neurol.* 154, 31-40.
20. File, S, Mahal, A, Mangiarini, M, Bates, GP (1998) Striking changes in anxiety in Huntington's disease transgenic mice. *Brain Res.* 805 (1-2), 234-240.
21. Davies SW, Turmaine M, Cozens B, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP (1997) Formation of neuronal intranuclear inclusions (NII) underlies the neurological dysfunction in mice transgenic for the HD mutation. *Cell* 90 (3), 537-548.
22. Mangiarini L, Sathasivam K, Mahal A, Mott R, Seller M, Bates GP (1997) Instability of Highly Expanded CAG Repeats in Mice Transgenic for the Huntington's Disease Mutation. *Nature Genet* 15 (2), 197-200